Influenza

 

Antiviral medications for influenza: Information for Health care providers

Live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) for children: Information for health care providers on the 2016 – 2017 recommendations

 

Table of Contents

 

 

Influenza Vaccine

The best protection against influenza virus is immunization.  

Health care providers play an important role in preventing the spread of influenza and promoting the benefits of influenza vaccine.   

Research * demonstrates that health care providers are important sources of influence for clients decisions to get the influenza vaccine.  Research demonstrates, when a health care provider recommends influenza immunization, 8 out of 10 clients take their health care provider’s advice and get immunized.

* Reference: Public Health Agency of Canada http://healthycanadians.gc.ca/diseases-conditions-maladies-affections/disease-maladie/flu-grippe/professionals-professionnels-eng.php retrieved October 6 2014

 

 

Statement of Seasonal Influenza Vaccine

 

 

World Health Organization

It is recommended that trivalent vaccines for use in the 2016 influenza season (southern hemisphere winter) contain the following: •   an A/California/7/2009 (H1N1)-like virus;

  • an A/Hong Kong/4801/2014 (H3N2)-like virus;
  • a B/Brisbane/60/2008-like virus.

It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Phuket/3073/2013-like virus. 

 

 

Ontario Ministry of Health and Long-term Care Recommendations:

 

Influenza vaccine is available in early October to health care providers for the immunization of priority groups.

The priority groups include:

  1. Individuals at high risk of influenza-related complications or more likely to require hospitalization:
  • Young children under five years of age (especially those younger than two years of age);
  • Children (age 6 months to 18 years) with neurologic or neurodevelopmental conditions or undergoing treatment with acetylsalicylic acid for long periods;
  • Adults 65 years of age and older;
  • Individuals of any age who are residents in long-term care home (LTCH) or other chronic care facilities;
  • Individuals with underlying health conditions (e.g., cardiac/pulmonary disorders, renal disease, morbid obesity, diabetes and cancer or weakened immune systems);
  • Pregnant women; and
  • Aboriginal Peoples.
  1. Individuals capable of transmitting influenza to those at high risk:
  • Health care workers;
  • Household contacts of those at high risk; and
  • Persons who provide child care to kids less than five years of age.
  1.  Swine and poultry industry workers receive influenza immunization as early as possible.

For the 2016/2017 UIIP, Ontario will offer quadrivalent influenza vaccines and trivalent influenza vaccines, for specific age groups:

 

Agriflu® /Fluviral®

Influvac®

Fluad®

FluLaval Tetra® /

Fluzone Quadrivalent®

Vaccine Formulation

Trivalent inactivated vaccine

(TIV)

Trivalent inactivated vaccine

(TIV)

Trivalent inactivated vaccine (adjuvanted)

(TIV-adjuvanted)

Quadrivalent inactivated vaccine (QIV)

Dosage

0.5mL

0.5mL

0.5mL

0.5mL

Route of Administration

Intramuscular Injection

Intramuscular Injection

Intramuscular Injection

Intramuscular Injection

Age Indication

6 months and older*

18 years and older

65 years and older

6 months through 17 years

Potential Allergens

Agriflu:

Egg protein^, Kanamycin, Neomycin, Thimerosal

Fluviral:

Egg protein^, Thimerosal

Egg protein^, Chicken protein, Gentamicin

Egg protein^, Chicken protein, Kanamycin, Neomycin

FluLaval:

Egg protein^, Thimerosal

Fluzone:

Egg protein^, Thimerosal

Package Description

Multi-dose vial

Single dose syringe

Single dose syringe

Multi-dose vial

Once punctured, discard vial after

28 days

n/a

n/a

FluLaval:28 days

Fluzone:

expiry date on vial

Package Dimensions

(length x width x height)

3cm x 3cm x 7cm

18.8cm x 15.2cm x 1.7cm

10.8cm x 10.2cm x 4.4cm

3cm x 3cm x 6cm

* Unless specifically requested the TIVs are primarily targeted to adults 18 years of age and older.

^ Egg allergy is not a contraindication to receiving influenza vaccines (see National Advisory Committee on Immunization Influenza Statement available at http://www.phac-aspc.gc.ca/naci-ccni/flu-2016-grippe-eng.php#ii7 )

 

Specific Age Groups Eligible for the Publicly Funded Influenza Vaccine:

Age Group

Recommended Vaccine

Alternative Vaccine

6 through 17 years

QIV

TIV (if requested or if QIV is not available, only the TIVs Agriflu® or Fluviral® can be used in this population)

18 years and older

TIV

None

65 years and older who reside in LTCH

TIV-adjuvanted

TIV (if requested or if TIV-adjuvanted is not available)

Previously unvaccinated children less than 9 years of age require two doses of seasonal influenza vaccine, with a minimum interval of four weeks between doses. Eligible children less than 9 years of age, who have properly received one or more doses of seasonal influenza vaccine in the past, are recommended to receive one dose per season thereafter. Please note that influenza vaccines are interchangeable. The 2 dose initial series does not have to be the same influenza vaccine product; however QIV is preferred for both doses.

 

 

Influenza Vaccine Product Monographs

 

 

Influenza Immunization Reporting

Healthcare worker influenza immunization rates are to be reported by December 15th each year.  Once data is collected, the information will be posted under our outbreaks page.

 

 

Adverse Events Following Immunizations(AEFI):

 

 

Educational Resources:

 

Surveillance

 

Antivirals

 

Pandemic Planning

 

Share this page